TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Grand Pharmaceutical Group Limited ( (HK:0512) ) has issued an update.
Grand Pharmaceutical Group Limited has announced the first commercial prescription of UI-SEEK, an early detection product for urinary system tumors, in Mainland China. This product, developed with AcornMed, is the first of its kind in China to use a dual mechanism of methylation and gene mutation for non-invasive tumor diagnosis. The company aims to strengthen its market position in urological tumor diagnosis and expand its product portfolio to meet clinical needs in early detection and treatment of various cancers.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company involved in the nuclear medicine anti-tumor diagnosis and treatment industry. It collaborates with AcornMed Biotechnology Co., Ltd. to develop products for early tumor detection and precision medical testing, focusing on unmet clinical needs in cancer diagnosis and treatment.
YTD Price Performance: 27.72%
Average Trading Volume: 9,351,944
Technical Sentiment Signal: Sell
Current Market Cap: HK$20.8B
For an in-depth examination of 0512 stock, go to TipRanks’ Stock Analysis page.